表紙
市場調查報告書
商品編碼
1064417

硬皮症治療的全球市場:2022年∼2026年

Global Scleroderma Therapeutics Market 2022-2026

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球硬皮症治療的市場規模在2022年∼2026年間,預測將成長到5億7,387萬美元,在預測期間中預計將以5.44%的年複合成長率增長。

市場成長的主要因素有高未滿足的醫療需求、提高認識的努力以及研發活動資金的增加。

本報告涵括硬皮症治療的全球市場的整體分析,提供市場規模與預測,趨勢,成長促進因素,課題,及約25家供應商分析等資訊。

目錄

第1章 摘要整理

  • 市場概要

第2章 市場形勢

  • 市場生態系統

第3章 市場規模

  • 市場定義
  • 市場區隔分析
  • 2021年的市場規模
  • 市場預測:從2021年∼2026年的預測

第4章 波特的五力分析

  • 五力彙整
  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 競爭的威脅
  • 市場情況

第5章 市場區隔:各疾病類型

  • 市場區隔
  • 各疾病類型比較
  • 局部性硬皮症:市場規模與預測(2021年∼2026年)
  • 全身性硬皮症:市場規模與預測(2021年∼2026年)
  • 各疾病類型的市場機會

第6章 客戶形勢

  • 客戶形勢概要

第7章 各地區形勢

  • 各地區市場區隔
  • 各地區的比較
  • 北美:市場規模與預測(2021年∼2026年)
  • 歐洲:市場規模與預測(2021年∼2026年)
  • 亞洲:市場規模與預測(2021年∼2026年)
  • 其他地區(ROW):市場規模與預測(2021年∼2026年)
  • 加拿大:市場規模與預測(2021年∼2026年)
  • 美國:市場規模與預測(2021年∼2026年)
  • 丹麥:市場規模與預測(2021年∼2026年)
  • 中國:市場規模與預測(2021年∼2026年)
  • 印度:市場規模與預測(2021年∼2026年)
  • 各地區形勢的市場機會

第8章 推動要素,課題,趨勢

  • 市場推動要素
  • 市場課題
  • 推動要素與課題的影響
  • 市場趨勢

第9章 業者情勢

  • 概要
  • 業者情勢
  • 混亂狀況
  • 產業的風險

第10章 供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Akashi Therapeutics
  • Argentis Pharmaceuticals LLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Castle Creek Biosciences Inc.
  • Chemomab Therapeutics Ltd.
  • Corbus Pharmaceuticals Holdings Inc.
  • Emerald Health Pharmaceuticals
  • F. Hoffmann La Roche Ltd.
  • Kadmon Holdings Inc.

第11章 附錄

  • 調查範圍
  • 包含與排除清單
  • US$的匯率
  • 調查手法
  • 簡稱的清單
目錄
Product Code: IRTNTR72388

Technavio has been monitoring the scleroderma therapeutics market and it is poised to grow by $ 573.87 mn during 2022-2026, progressing at a CAGR of 5.44% during the forecast period. Our report on the scleroderma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet medical needs, rising focus on awareness-raising initiatives, and increased funding for R and D activities. In addition, high unmet medical needs are anticipated to boost the growth of the market as well.

The scleroderma therapeutics market analysis includes disease segment and geographic landscape.

Technavio's scleroderma therapeutics market is segmented as below:

By Disease Type

  • Localized Scleroderma
  • Systemic Scleroderma

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the introduction of stem cell therapy in scleroderma treatment as one of the prime reasons driving the scleroderma therapeutics market growth during the next few years. Also, the advent of novel therapies, partnerships, and strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the scleroderma therapeutics market covers the following areas:

  • Scleroderma therapeutics market sizing
  • Scleroderma therapeutics market forecast
  • Scleroderma therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading scleroderma therapeutics market vendors that include AbbVie Inc., Akashi Therapeutics, Amneal Pharmaceuticals Inc., Antares Pharma Inc., Argentis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Castle Creek Biosciences Inc., Chemomab Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc., Cumberland Pharmaceuticals Inc., Emerald Health Pharmaceuticals, F. Hoffmann La Roche Ltd., Kadmon Holdings Inc., Medexus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and The Procter and Gamble Co. Also, the scleroderma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Disease Type
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Disease Type

  • 5.1 Market segments
  • Exhibit 24: Chart on Disease Type - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Disease Type - Market share 2021-2026 (%)
  • 5.2 Comparison by Disease Type
  • Exhibit 26: Chart on Comparison by Disease Type
  • Exhibit 27: Data Table on Comparison by Disease Type
  • 5.3 Localized scleroderma - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • 5.4 Systemic scleroderma - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Disease Type
  • Exhibit 36: Market opportunity by Disease Type ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
  • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 40: Chart on Geographic comparison
  • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 Canada - Market size and forecast 2021-2026
  • Exhibit 58: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.8 US - Market size and forecast 2021-2026
  • Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.9 Denmark - Market size and forecast 2021-2026
  • Exhibit 66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • 7.10 China - Market size and forecast 2021-2026
  • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.11 India - Market size and forecast 2021-2026
  • Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Akashi Therapeutics
  • Exhibit 85: Akashi Therapeutics - Overview
  • Exhibit 86: Akashi Therapeutics - Product / Service
  • Exhibit 87: Akashi Therapeutics - Key offerings
  • 10.4 Argentis Pharmaceuticals LLC
  • Exhibit 88: Argentis Pharmaceuticals LLC - Overview
  • Exhibit 89: Argentis Pharmaceuticals LLC - Product / Service
  • Exhibit 90: Argentis Pharmaceuticals LLC - Key offerings
  • 10.5 Boehringer Ingelheim International GmbH
  • Exhibit 91: Boehringer Ingelheim International GmbH - Overview
  • Exhibit 92: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 93: Boehringer Ingelheim International GmbH - Key news
  • Exhibit 94: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 95: Boehringer Ingelheim International GmbH - Segment focus
  • 10.6 Bristol-Myers Squibb Co.
  • Exhibit 96: Bristol-Myers Squibb Co. - Overview
  • Exhibit 97: Bristol-Myers Squibb Co. - Product / Service
  • Exhibit 98: Bristol-Myers Squibb Co. - Key offerings
  • 10.7 Castle Creek Biosciences Inc.
  • Exhibit 99: Castle Creek Biosciences Inc. - Overview
  • Exhibit 100: Castle Creek Biosciences Inc. - Product / Service
  • Exhibit 101: Castle Creek Biosciences Inc. - Key offerings
  • 10.8 Chemomab Therapeutics Ltd.
  • Exhibit 102: Chemomab Therapeutics Ltd. - Overview
  • Exhibit 103: Chemomab Therapeutics Ltd. - Business segments
  • Exhibit 104: Chemomab Therapeutics Ltd. - Key offerings
  • Exhibit 105: Chemomab Therapeutics Ltd. - Segment focus
  • 10.9 Corbus Pharmaceuticals Holdings Inc.
  • Exhibit 106: Corbus Pharmaceuticals Holdings Inc. - Overview
  • Exhibit 107: Corbus Pharmaceuticals Holdings Inc. - Business segments
  • Exhibit 108: Corbus Pharmaceuticals Holdings Inc. - Key offerings
  • Exhibit 109: Corbus Pharmaceuticals Holdings Inc. - Segment focus
  • 10.10 Emerald Health Pharmaceuticals
  • Exhibit 110: Emerald Health Pharmaceuticals - Overview
  • Exhibit 111: Emerald Health Pharmaceuticals - Business segments
  • Exhibit 112: Emerald Health Pharmaceuticals - Key offerings
  • Exhibit 113: Emerald Health Pharmaceuticals - Segment focus
  • 10.11 F. Hoffmann La Roche Ltd.
  • Exhibit 114: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 115: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 116: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 117: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 118: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.12 Kadmon Holdings Inc.
  • Exhibit 119: Kadmon Holdings Inc. - Overview
  • Exhibit 120: Kadmon Holdings Inc. - Product / Service
  • Exhibit 121: Kadmon Holdings Inc. - Key offerings

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 122: Inclusions checklist
  • Exhibit 123: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 124: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 125: Research methodology
  • Exhibit 126: Validation techniques employed for market sizing
  • Exhibit 127: Information sources
  • 11.5 List of abbreviations
  • Exhibit 128: List of abbreviations

Exhibits

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Disease Type
  • Exhibits6: Executive Summary - Chart on Incremental Growth
  • Exhibits7: Executive Summary - Data Table on Incremental Growth
  • Exhibits8: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits9: Parent market
  • Exhibits10: Market Characteristics
  • Exhibits11: Offerings of vendors included in the market definition
  • Exhibits12: Market segments
  • Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits17: Five forces analysis - Comparison between 2021 and 2026
  • Exhibits18: Bargaining power of buyers - Impact of key factors in 2021 and 2026
  • Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • Exhibits23: Chart on Market condition - Five forces 2021 and 2026
  • Exhibits24: Chart on Disease Type - Market share 2021-2026 (%)
  • Exhibits25: Data Table on Disease Type - Market share 2021-2026 (%)
  • Exhibits26: Chart on Comparison by Disease Type
  • Exhibits27: Data Table on Comparison by Disease Type
  • Exhibits28: Chart on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits29: Data Table on Localized scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits30: Chart on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Data Table on Localized scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits32: Chart on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits33: Data Table on Systemic scleroderma - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Chart on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Data Table on Systemic scleroderma - Year-over-year growth 2021-2026 (%)
  • Exhibits36: Market opportunity by Disease Type ($ million)
  • Exhibits37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits40: Chart on Geographic comparison
  • Exhibits41: Data Table on Geographic comparison
  • Exhibits42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits58: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits59: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits60: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits61: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits62: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits63: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits64: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibits65: Data Table on US - Year-over-year growth 2021-2026 (%)
  • Exhibits66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibits67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
  • Exhibits68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibits69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)
  • Exhibits70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibits73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • Exhibits74: Chart on India - Market size and forecast 2021-2026 ($ million)
  • Exhibits75: Data Table on India - Market size and forecast 2021-2026 ($ million)
  • Exhibits76: Chart on India - Year-over-year growth 2021-2026 (%)
  • Exhibits77: Data Table on India - Year-over-year growth 2021-2026 (%)
  • Exhibits78: Market opportunity By Geographical Landscape ($ million)
  • Exhibits79: Impact of drivers and challenges in 2021 and 2026
  • Exhibits80: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits81: Overview on factors of disruption
  • Exhibits82: Impact of key risks on business
  • Exhibits83: Vendors covered
  • Exhibits84: Matrix on vendor position and classification
  • Exhibits85: Akashi Therapeutics - Overview
  • Exhibits86: Akashi Therapeutics - Product / Service
  • Exhibits87: Akashi Therapeutics - Key offerings
  • Exhibits88: Argentis Pharmaceuticals LLC - Overview
  • Exhibits89: Argentis Pharmaceuticals LLC - Product / Service
  • Exhibits90: Argentis Pharmaceuticals LLC - Key offerings
  • Exhibits91: Boehringer Ingelheim International GmbH - Overview
  • Exhibits92: Boehringer Ingelheim International GmbH - Business segments
  • Exhibits93: Boehringer Ingelheim International GmbH - Key news
  • Exhibits94: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibits95: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibits96: Bristol-Myers Squibb Co. - Overview
  • Exhibits97: Bristol-Myers Squibb Co. - Product / Service
  • Exhibits98: Bristol-Myers Squibb Co. - Key offerings
  • Exhibits99: Castle Creek Biosciences Inc. - Overview
  • Exhibits100: Castle Creek Biosciences Inc. - Product / Service
  • Exhibits101: Castle Creek Biosciences Inc. - Key offerings
  • Exhibits102: Chemomab Therapeutics Ltd. - Overview
  • Exhibits103: Chemomab Therapeutics Ltd. - Business segments
  • Exhibits104: Chemomab Therapeutics Ltd. - Key offerings
  • Exhibits105: Chemomab Therapeutics Ltd. - Segment focus
  • Exhibits106: Corbus Pharmaceuticals Holdings Inc. - Overview
  • Exhibits107: Corbus Pharmaceuticals Holdings Inc. - Business segments
  • Exhibits108: Corbus Pharmaceuticals Holdings Inc. - Key offerings
  • Exhibits109: Corbus Pharmaceuticals Holdings Inc. - Segment focus
  • Exhibits110: Emerald Health Pharmaceuticals - Overview
  • Exhibits111: Emerald Health Pharmaceuticals - Business segments
  • Exhibits112: Emerald Health Pharmaceuticals - Key offerings
  • Exhibits113: Emerald Health Pharmaceuticals - Segment focus
  • Exhibits114: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits115: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits116: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits117: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits118: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits119: Kadmon Holdings Inc. - Overview
  • Exhibits120: Kadmon Holdings Inc. - Product / Service
  • Exhibits121: Kadmon Holdings Inc. - Key offerings
  • Exhibits122: Inclusions checklist
  • Exhibits123: Exclusions checklist
  • Exhibits124: Currency conversion rates for US$
  • Exhibits125: Research methodology
  • Exhibits126: Validation techniques employed for market sizing
  • Exhibits127: Information sources
  • Exhibits128: List of abbreviations